KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

TherapeuticsMD (TXMD) Accumulated Depreciation & Amortization (2016 - 2023)

TherapeuticsMD's Accumulated Depreciation & Amortization history spans 14 years, with the latest figure at $2.5 million for Q3 2023.

  • For Q3 2023, Accumulated Depreciation & Amortization fell 16.46% year-over-year to $2.5 million; the TTM value through Sep 2023 reached $2.5 million, down 16.46%, while the annual FY2022 figure was $2.4 million, 24.05% up from the prior year.
  • Accumulated Depreciation & Amortization reached $2.5 million in Q3 2023 per TXMD's latest filing, up from $2.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.0 million in Q3 2022 to a low of $686680.0 in Q2 2019.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.9 million, with a median of $2.1 million recorded in 2021.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 98.78% in 2020, then fell 16.46% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $968824.0 in 2019, then soared by 79.7% to $1.7 million in 2020, then grew by 13.21% to $2.0 million in 2021, then grew by 24.05% to $2.4 million in 2022, then rose by 2.37% to $2.5 million in 2023.
  • Per Business Quant, the three most recent readings for TXMD's Accumulated Depreciation & Amortization are $2.5 million (Q3 2023), $2.5 million (Q2 2023), and $2.5 million (Q1 2023).